2. Academic Validation
  3. CDCP1: A promising diagnostic biomarker and therapeutic target for human cancer

CDCP1: A promising diagnostic biomarker and therapeutic target for human cancer

  • Life Sci. 2022 Jul 15:301:120600. doi: 10.1016/j.lfs.2022.120600.
Xiao Qi 1,  Jing Gao 2,  Zihao Li 3,  Guangxin Zhang 4,  Jialin Li 5,  Yilin Fu 6,  Mingjun Cai 7,  Hongda Wang 8,  Ti Tong 9
Affiliations

Affiliations

  • 1 Department of thoracic surgery, The Second Hospital of Jilin University, Changchun, Jilin 130041, China. Electronic address: qixiao20@mails.jlu.edu.cn.
  • 2 State Key Laboratory of Electroanalytical Chemistry, Research Center of Biomembranomics, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin 130022, China. Electronic address: gaojing@ciac.ac.cn.
  • 3 Department of thoracic surgery, The Second Hospital of Jilin University, Changchun, Jilin 130041, China. Electronic address: zhl19@mails.jlu.edu.cn.
  • 4 Department of thoracic surgery, The Second Hospital of Jilin University, Changchun, Jilin 130041, China. Electronic address: guangxinzhang@jlu.edu.cn.
  • 5 Department of Neurology, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130012, China.
  • 6 Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China. Electronic address: fuyl18@mails.jlu.edu.cn.
  • 7 State Key Laboratory of Electroanalytical Chemistry, Research Center of Biomembranomics, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin 130022, China. Electronic address: caimingjun@ciac.ac.cn.
  • 8 State Key Laboratory of Electroanalytical Chemistry, Research Center of Biomembranomics, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin 130022, China; University of Science and Technology of China, Hefei, Anhui 230027, China; Laboratory for Marine Biology and Biotechnology, Qing dao National Laboratory for Marine Science and Technology, Wenhai Road, Aoshanwei, Jimo, Qingdao, Shandong 266237, China. Electronic address: hdwang@ciac.ac.cn.
  • 9 Department of thoracic surgery, The Second Hospital of Jilin University, Changchun, Jilin 130041, China. Electronic address: tongti@jlu.edu.cn.
PMID: 35504333 DOI: 10.1016/j.lfs.2022.120600
Abstract

CUB domain-containing protein 1 (CDCP1), as an emerging transmembrane protein, is overexpressed in a variety of malignant tumors including respiratory tumors, digestive system cancers, hematological malignancies and urogenital cancers. Several cancer-related proteins have been reported to interact with CDCP1. It acts as a crucial hub in multiple classical signaling pathways of tumorigenesis and progression. Its overexpression and activation are also associated with prognosis and drug resistance. Due to its important roles in malignant tumors, CDCP1 is expected to be a promising therapeutic target for treatment and a new biomarker for diagnosis. In this article, we review the roles of CDCP1 in diagnosis and management of malignant tumors, and also its regulation in several essential tumor-related pathways.

Keywords

Biomarker; CUB domain-containing protein 1; Cancers; Metastases; Targeted therapy; Tumorigenesis.

Figures
Products